Microbot Medical enhances LIBERTY® robotic system portfolio with acquisition of new FDA-approved devices

Microbot Medical enhances LIBERTY® robotic system portfolio with acquisition of new FDA-approved devices

Microbot Medical Inc.

Integration with the LIBERTY® Robotic System and One & Done™ technology may accelerate robotic adoption in the future; Represents an additional growth opportunity by reaching $500 million in the CTO market.1 By expanding the robotic ecosystem of endovascular procedures

HINGHAM, MA, Oct 7, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today, as a continuation of its recent regulatory and future business activities, along with its strategic mission to enable access to numerous endovascular procedures globally, has acquired the assets of Nitiloop Ltd. privately owned. The acquisition includes the NovaCross™ family of Microcatheters (NovaCross CTO, NovaCross Xtreme, and NovaCross BTK), an FDA-approved family of devices intended to facilitate intraluminal placement of conventional and steerable guidewires beyond stenotic lesions, including: That chronic total obstruction (CTO), prior to PTCA or stent intervention.

The NovaCross™ Microcatheter family is expected, as a standalone device or when integrated with the company’s One & Done™ technology, to create a suite of related action suites customized for the LIBERTY® Robotic System. The LIBERTY Robotic System is the first ever robotic, single-use system with remote start capabilities and a small footprint designed to reduce capital investment and catheter lab space requirements. The company expects this integration to help revolutionize the way vascular procedures are performed and standardized, while removing barriers to access and increasing the adoption rate of robots in the vascular space.

Integrating technologies, such as the NovaCross™ Microcatheter family, fits well with the company’s ecosystem strategy by allowing it to compete in the robotics market as well as tools for endovascular procedures, with the goal of integrating imaging and big data capabilities in the future. The company believes that realizing the LIBERTY Robotic System ecosystem will allow Microbot Medical to advance the adoption of robotics in the intravascular space globally.

“The addition of the FDA’s innovative microcatheter family (Nitiloop) complements the unique robotic ecosystem we are creating for endovascular procedures. This is expected to further assist us in implementing our strategic plan to become a full procedure-based company, allowing Microbot Medical To be competitive throughout the intravascular robotic space, commented Harel Gadot, Chairman, President and CEO.” We believe that the NovaCross™ family of products, once integrated into our existing technology platforms with the LIBERTY Robotic System and One & Done technology In the future, it has the potential to standardize vascular procedures globally and may finally allow access to robotic technology for the millions who are in dire need of life-saving treatment.”

1 Market research study from Insight Partners entitled “COPD Market”

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a preclinical medical device company specializing in transformational micro-robotic technologies, primarily focusing on both natural and artificial lumens within the human body. Microbot’s existing technology platforms provide the basis for the development of the Multi-Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham and Yossi Bornstein with the goal of improving clinical outcomes for patients and increasing accessibility through the use of microrobot technologies. More information about Microbot Medical is available at http://www.microbotmedical.com.

safe haven

Data on future financial and/or operating results, future growth in research, technology, and clinical development, and potential opportunities for Microbot Medical Inc. and its affiliates, along with other statements about future expectations, beliefs, objectives, plans or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the federal securities laws. Any statements that are not historical facts (including, but not limited to, statements that contain words such as “will,” “believe,” “plan,” “expect,” “expect,” and “estimate”) should also be considered forward-looking. data. Forward-looking statements involve risks and uncertainties, including, but not limited to, market conditions, risks inherent in the development and/or marketing of potential products, including the LIBERTY family and NovaCross™ Microcatheter, and the results of its studies to evaluate the company’s other existing and future technologies, Any failure or inability to appoint physicians and clinicians to serve as primary investigators to conduct an early feasibility study of the company’s self-cleaning shunt that could adversely affect or delay this study, uncertainty in preclinical trial results and clinical or regulatory pathways and regulatory approvals, failure or inability to Incorporating the NovaCross™ Microcatheter family, the uncertainty created by the COVID-19 pandemic, the need and ability to obtain future capital, and the preservation of intellectual property rights. Additional information about the risks to Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports to the Securities and Exchange Commission (SEC), available on the SEC’s website at www.sec.gov. Microbot Medical disclaims any intention or obligation to update these forward-looking statements, except as required by law.

Investor contact:

Michael Bolivio
EVC . group

#Microbot #Medical #enhances #LIBERTY #robotic #system #portfolio #acquisition #FDAapproved #devices

Leave a Comment

Your email address will not be published. Required fields are marked *